Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

27.48 -0.09 (-0.34%)
Streaming Delayed Price Updated: 10:18 AM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial ↗
Pfizer's Braftovi combo improves survival in advanced colorectal cancer trial. 
Via Benzinga
News headline image
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based... 
Via Finterra
Topics Economy Intellectual Property
News headline image
The Great Inflation Thaw: US Price Pressures Hit Five-Year Low as Federal Reserve Eyes 2026 Pivot
The United States economy reached a long-awaited milestone this week as the Bureau of Labor Statistics reported that headline inflation fell to 2.4% in January 2026, with the core Consumer Price Index... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that... 
Via MarketMinute
Topics Intellectual Property
News headline image
3 S&P 500 Stocks Worth Investigating
The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innovate and expand, setting themselves up for... 
Via StockStory
Topics Stocks
News headline image
What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years? ↗
Eli Lilly continues to pursue smart acquisitions for the long term. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results
Moderna Inc. (NASDAQ: MRNA) shares jumped 8% in early trading on February 13, 2026, after the biotechnology pioneer reported fourth-quarter 2025 financial results that exceeded Wall Street’s... 
Via MarketMinute
Topics Earnings
News headline image
Hospitals Stand Tall: Healthcare Sector Becomes Safe Haven Amid "Warsh Shock" and Tech Volatility
In a day defined by sharp reversals and a fundamental recalibration of market leadership, the healthcare sector emerged as the primary beneficiary of a massive capital rotation on February 13, 2026.... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind
As the opening bell rang on February 13, 2026, the divergence between the U.S. technology and healthcare sectors reached a historic fever pitch, signaling a fundamental shift in how markets price... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 ↗
Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Healthcare’s Renaissance: Sector Outshines Tech as Policy Clarity Sparks Q4 Surge
The healthcare sector has staged a dramatic structural breakout, ending a multi-year period of relative stagnation to lead the global markets into 2026. After a powerful 10% gain in the final quarter... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
S&P 500 Breaches 7,000 Milestone: AI Megacaps Propel Market to Historic Heights
The financial world witnessed a watershed moment on January 28, 2026, as the S&P 500 index breached the 7,000-point threshold for the first time in history. This milestone, coming just fourteen months... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Zoetis Inc. (ZTS): Navigating Innovation and Safety in a Mature Animal Health Market
Zoetis Inc. (NYSE: ZTS) stands today as the undisputed global leader in animal health, a position it has fortified since its historic decoupling from Pfizer over a decade ago. As of February 12, 2026,... 
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
FDA Stuns Moderna with Refusal to Review Flu Vaccine, Sending Shares Tumbling 3.5%
Shares of Moderna, Inc. (NASDAQ: MRNA) fell 3.5% on February 12, 2026, as investors continued to digest the fallout from a rare and unexpected regulatory setback. The U.S. Food and Drug Administration... 
Via MarketMinute
Topics Earnings
News headline image
Zoetis’s (NYSE:ZTS) Q4 CY2025 Sales Top Estimates
Animal health company Zoetis (NYSE:ZTS) announced better-than-expected revenue in Q4 CY2025, with sales up 3% year on year to $2.39 billion. The company expects the full year’s revenue to be around... 
Via StockStory
News headline image
Pfizer Reports Strong Earnings Outlook - Unusual Call Options Activity Shows Investors Are Bullish ↗
Pfizer, Inc. reported strong earnings and earnings guidance on Feb. 3. Large, unusual call option activity today shows that investors are bullish. 
Via Talk Markets
News headline image
Is Now the Best Time to Buy Pfizer Stock? ↗
It's worth taking a second look at the healthcare giant. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Reports Strong Earnings Outlook - Unusual Call Options Activity Shows Investors are Bullish
Pfizer reported strong earnings and earnings guidance. Large, unusual call option activity today, as noted in a Barchart report, indicates investors are bullish. 
Via Barchart.com
News headline image
Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip. ↗
Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks. 
Via The Motley Fool
News headline image
Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology
Today, February 11, 2026, marks a volatile chapter for Moderna, Inc. (NASDAQ: MRNA). The biotechnology pioneer, which became a household name during the COVID-19 pandemic, finds itself at a critical... 
Via Finterra
Topics Artificial Intelligence Initial Public Offering Intellectual Property
News headline image
Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know ↗
The GLP-1 market is a massive opportunity in healthcare, and many companies are vying for a piece of it. 
Via The Motley Fool
News headline image
Is 2026 the Year of Dividend Stocks? These 2 Income-Focused ETFs Have Been Soaring Past the S&P 500 ↗
These funds both pay more than 3% and have been beating the market this year. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
CVS Health Navigates a Stormy 2026: Record Revenue Tempered by Medicare Advantage Costs and PBM Turmoil
In a pivotal earnings report delivered on February 10, 2026, CVS Health (NYSE: CVS) showcased a complex narrative of financial resilience and operational headwinds. While the healthcare giant posted... 
Via MarketMinute
Topics Economy
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026
Date: February 10, 2026 Introduction AstraZeneca PLC (NASDAQ: AZN; LSE: AZN) stands today at a critical crossroads of pharmaceutical history. Long recognized as the crown jewel of British... 
Via Finterra
Topics Artificial Intelligence Economy Fraud
News headline image
Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse
February 10, 2026 Introduction As of February 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a pivotal juncture. Five years after its high-profile inception, the company has shed its skin as a... 
Via Finterra
Topics Economy World Trade
News headline image
Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗
The stock has climbed in the triple digits over the past three years. 
Via The Motley Fool
News headline image
5 Revealing Analyst Questions From Pfizer’s Q4 Earnings Call
Pfizer closed the fourth quarter with revenue ahead of Wall Street expectations, but the market reacted negatively due to a combination of year-over-year sales decline and shrinking operating margins.... 
Via StockStory
Topics Artificial Intelligence Earnings
News headline image
Should You Buy Pfizer's Stock for Its 6.3%-Yielding Dividend? ↗
The stock has been fairly stable over the past year. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.